How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,375 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Cushing reflex

Cushing reflex Cushing reflex - Wikipedia Cushing reflex From Wikipedia, the free encyclopedia Cushing reflex (also referred to as the vasopressor response , the Cushing effect , the Cushing reaction , the Cushing phenomenon , the Cushing response , or Cushing's Law ) is a physiological nervous system response to increased (ICP) that results in of increased blood pressure, irregular breathing, and . It is usually seen in the terminal stages of acute and may indicate imminent . It can also (...) be indicative of insufficient to the brain ( ) as well as compression of . In response to rising intracranial pressure (ICP), respiratory cycles change in regularity and rate. Different patterns indicate a different location of the brain where the injury occurred. The increase in is exhibited as an increase in rate rather than depth of ventilation, so the Cushing reflex is often associated with slow, irregular breathing. As a result of the now defective regulation of heart rate and blood pressure

2012 Wikipedia

162. Cushing's syndrome Full Text available with Trip Pro

such as in the and around the neck, as well as in the axilla. Untreated Cushing's syndrome can lead to and increased . Cortisol can also exhibit activity in high concentrations, worsening the hypertension and leading to (common in ectopic ACTH secretion) and (increased Na+ ions concentration in plasma). Furthermore, excessive cortisol may lead to disturbances, opportunistic infections, and impaired wound healing related to cortisol's suppression of the immune and inflammatory responses. is also an issue in Cushing's (...) of glucocorticoid medication. Cushing's syndrome results from some derangement of the body's own system of secreting cortisol. Normally, is released from the when necessary to stimulate the release of cortisol from the . In pituitary Cushing's, a benign pituitary adenoma secretes ACTH. This is also known as Cushing's disease and is responsible for 70% of endogenous Cushing's syndrome. In adrenal Cushing's, excess cortisol is produced by adrenal gland tumors, hyperplastic adrenal glands, or adrenal glands

2012 Wikipedia

163. Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression

Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Repeated (...) Partial Sleep Deprivation to Augment SSRI Response in Depression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01545843 Recruitment Status : Completed First Posted : March 7, 2012 Results First Posted : January 30, 2015 Last Update Posted : December 8, 2017 Sponsor: University of Michigan Information

2012 Clinical Trials

164. Cortisol and Nutritional Sympathetic Responsiveness

Cortisol and Nutritional Sympathetic Responsiveness Cortisol and Nutritional Sympathetic Responsiveness - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cortisol and Nutritional Sympathetic Responsiveness (...) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01620684 Recruitment Status : Unknown Verified September 2014 by Nora E. Straznicky, Baker Heart Research Institute. Recruitment status was: Recruiting First Posted : June 15, 2012 Last Update Posted : September 9, 2014 Sponsor: Baker Heart Research

2012 Clinical Trials

165. Acute metabolic response to human growth hormone in different types of dwarfism. Full Text available with Trip Pro

Acute metabolic response to human growth hormone in different types of dwarfism. 5339170 1967 09 03 2018 11 13 0007-1447 3 5559 1967 Jul 22 British medical journal Br Med J Acute metabolic response to human growth hormone in different types of dwarfism. 196-9 Melvin K E KE Wright A D AD Hartog M M Antcliff A C AC Copestake A M AM Fraser T R TR eng Clinical Trial Journal Article England Br Med J 0372673 0007-1447 0 Insulin 9002-72-6 Growth Hormone N762921K75 Nitrogen SY7Q814VUP Calcium (...) V27W9254FZ Cortisone AIM IM Adolescent Adult Aged Arthritis, Juvenile metabolism Asthma metabolism Blood Urea Nitrogen Body Weight Bone Development drug effects Calcium urine Carcinoma metabolism Child Clinical Trials as Topic Cortisone adverse effects Cushing Syndrome metabolism Dwarfism drug therapy metabolism Dwarfism, Pituitary metabolism Female Growth Hormone blood therapeutic use Humans Hypoglycemia metabolism Insulin Male Middle Aged Nitrogen urine Osteoporosis metabolism Turner Syndrome

1967 British medical journal

166. Response to stress. Full Text available with Trip Pro

Response to stress. 4319949 1970 12 21 2018 11 30 0007-1447 4 5728 1970 Oct 17 British medical journal Br Med J Response to stress. 176 Besser G M GM eng Journal Article England Br Med J 0372673 0007-1447 0 Insulin 9002-60-2 Adrenocorticotropic Hormone AIM IM Adrenocorticotropic Hormone metabolism Cushing Syndrome etiology metabolism Humans Hypoglycemia chemically induced Insulin Stress, Physiological metabolism 1970 10 17 1970 10 17 0 1 1970 10 17 0 0 ppublish 4319949 PMC1819921 Lancet. 1965

1970 British medical journal

167. ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE Full Text available with Trip Pro

ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE 16561804 2006 05 25 2018 12 01 0021-9193 58 4 1949 Oct Journal of bacteriology J. Bacteriol. ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE. 433-42 Cushing J E JE University of California, Santa Barbara College, Department of Biology, Santa Barbara, California. Schwartz M M Bennett R R eng Journal Article United States J Bacteriol 2985120R 0021-9193 0 Indoles 8724FJW4M5 indole OM Indoles

1949 Journal of bacteriology

168. V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle Full Text available with Trip Pro

V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle 16577355 2006 06 01 2008 11 20 0027-8424 17 5 1931 May Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle. 248-53 Cushing H H Harvard Medical School and Peter Bent Brigham Hospital. eng Journal

1931 Proceedings of the National Academy of Sciences of the United States of America

169. II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles Full Text available with Trip Pro

II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles 16577341 2006 06 01 2008 11 20 0027-8424 17 4 1931 Apr Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles. 171-7 Cushing H H Peter Bent Brigham Hospital and Harvard

1931 Proceedings of the National Academy of Sciences of the United States of America

170. Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of final report A16-70 Version 1.0 Biologics for rheumatoid arthritis 23 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - This report was prepared in collaboration with external experts. The responsibility for the contents of the report lies solely with IQWiG (...) is not relevant for the comparative benefit assessment of the biologics, since only 1 biologic (etanercept) is approved as first-line treatment without combination with MTX. b: Rituximab is approved in patients with inadequate response or intolerance to other DMARDs including 1 or more treatments with TNF inhibitors. ? Approved in the line of treatment (as of 28 June 2017). - Not approved in the line of treatment (as of 28 June 2017.) DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; TNF: tumour

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

171. Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment: ? Sascha Abbas ? Michaela Florina Kerekes ? Inga Overesch ? Regine Potthast ? Min Ripoll ? Anke Schulz ? Corinna ten Thoren ? Volker Vervölgyi Keywords: benralizumab, asthma, benefit assessment Extract of dossier assessment A18-11 Version1.0 (...) of inadequate treatment of severe asthma does not comply with an ACT in severe refractory eosinophilic asthma if the option for treatment escalation is still available. The therapeutic indication also comprises patients for whom there is no further escalation option for their ongoing treatment, however. c: OCS should only be used on a short-term basis and in their lowest effective dose. It should be ensured in the OCS treatment of asthma that the OCS dosage does not permanently exceed the Cushing threshold

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

172. Testosterone Testing - Protocol

for the investigation and diagnosis of female hyperandrogenism is beyond the scope of this document. Indications for urgent or non-urgent referral are outlined in Table 2 below. Monitoring Response to Treatment in Women Women receiving treatment for hyperandrogenism: Response to treatment of hyperandrogenism in women is clinical. Therefore, testing serum total testosterone and cBAT in patients treated for hyperandrogenism is not recommended unless a concrete cause has been identified, such as non-classical (...) . Men Women , Confirmed or suspected: Hypothalamic/pituitary tumour* Hyperprolactinemia* Hemochromatosis Idiopathic hypogonadotropic hypogonadism Cryptorchidism, anorchia Genetic conditions including Klinefelter syndrome, Kallmann syndrome, myotonic dystrophy Male factor infertility Confirmed or suspected: Rapid virilisation/rapid hair loss* Symptoms consistent androgen-secreting tumour of adrenal or ovarian origin* Cushing syndrome* Acromegaly* Congenital adrenal hyperplasia (CAH) Polycystic ovary

2019 Clinical Practice Guidelines and Protocols in British Columbia

173. Guidelines on Supraventricular Tachycardia (for the management of patients with) Full Text available with Trip Pro

of supraventricular tachycardia 9 Table 6 Differential diagnosis of narrow and wide QRS tachycardias 9 Table 7 Initial evaluation of the patient with supraventricular tachycardia 10 Table 8 Possible responses of narrow QRS tachycardia to vagal manoeuvres and adenosine 13 Table 9 Summary of key electrocardiographic criteria that suggest ventricular tachycardia rather than supraventricular tachycardia in wide complex tachycardia 14 Table 10 Causes of physiological sinus tachycardia 19 Table 11 Average success (...) QRS tachycardia. 12 Figure 2 Responses of narrow complex tachycardias to adenosine. 13 Figure 3 Examples of positive and negative chest lead concordance. 15 Figure 4 Acute therapy of narrow QRS tachycardia in the absence of an established diagnosis. 17 Figure 5 Acute therapy of wide complex tachycardia in the absence of an established diagnosis 18 Figure 6 Therapy of sinus tachycardias 20 Figure 7 Focal atrial tachycardia 22 Figure 8 Acute therapy of focal atrial tachycardia 23 Figure 9 Chronic

2019 European Society of Cardiology

174. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity

Symptoms and signs of hypogonadism LH FSH testosterone Androgen excess (women) Common Central obesity Irregular menses Hirsutism Acanthosis nigricans LH FSH oestradiol testosterone Cushing’s disease or Cushing’s syndrome Rare Central obesity Hypertension Type 2 diabetes 1 mg ODST Drug-induced endocrine dysfunction (e.g. lithium, anti-depressants, antipsychotics, glucocorticoids…) Common Psychiatric disorders Glucocorticoid therapy 1 mg ODST to exclude Cushing syndrome (except in glucocorticoid use (...) response (40) rather than the primary event (see also 5.2.4) (41). Thus, hyperthyrotropinaemia associated with obesity must be differentiated from auto-immune-related subclinical hypothyroidism. No study directly assessed the benefits and harms of screening versus no screening in obese populations (42). However, if ‘true’ hypothyroidism is present, it potentiates the risk of obesity to develop cardiovascular risk factors and features of metabolic syndrome (21). Hypothyroidism contributes

2020 European Society of Endocrinology

175. Clinical practice guideline for evaluation of psychosocial factors influencing recovery from adult orthopaedic trauma

This clinical practice guideline was funded exclusively through a research grant provided by the United States Department of Defense with no funding from outside commercial sources to support the development of this document. FDA Clearance Some drugs or medical devices referenced or described in this Clinical practice guideline may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility (...) and early referral for treatment. There appears to be low risk of harm in evaluating psychosocial risk factors. Support for how best to screen/evaluate for these factors and their effects is limited and requires further study. Barriers to psychosocial evaluation include, but are not limited to, lack of resources to properly assess the risk factor and impediments to patient response (e.g. cognitive deficits and patient refusal to participate). Future Research Current evidence regarding mental and social

2020 American Academy of Orthopaedic Surgeons

176. The promotion of well?being among children exposed to intimate partner violence: A systematic review of interventions Full Text available with Trip Pro

, Forman‐Hoffman et al. ( ) conducted a comparative effectiveness review of interventions for children exposed to nonrelational traumatic events (e.g., accidents, natural disasters). Both of these reviews excluded evaluations of programs designed for children exposed to IPV, given the different nature of the trauma, resulting system responses, and intervention settings. For example, children exposed to IPV may not have access to resources traditionally offered to children engaged with the child

2019 Campbell Collaboration

177. Adrenal suppression

endogenous glucocorticoid excess (e.g., Cushing's syndrome after treatment). Even locally administered glucocorticoids may result in adrenal suppression. The adrenocorticotropic hormone stimulation test is generally the most useful test to detect adrenal suppression. Treatment consists of augmented corticosteroid therapy plus supportive care for any intercurrent stress or overt signs of adrenal insufficiency. Preventive measures include minimising corticosteroid dose and duration when possible (...) responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992 Jan 23;326(4):226-30. http://www.nejm.org/doi/full/10.1056/NEJM199201233260403#t=article http://www.ncbi.nlm.nih.gov/pubmed/1309389?tool=bestpractice.com History and exam presence of risk factors sudden cessation or rapid tapering of glucocorticoids hx of weight gain and increased appetite hx of depression, agitation, or sleep disorders hx of easy bruising fatigue, anorexia, or weight loss nausea or vomiting dizziness

2018 BMJ Best Practice

178. Assessment of hirsutism

=bestpractice.com Hair response to androgens varies from person to person and includes increase in follicle size, fibre diameter, and the amount of time spent in anagen (the growth-cycle phase). Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005 Dec 15;353(24):2578-88. http://www.ncbi.nlm.nih.gov/pubmed/16354894?tool=bestpractice.com Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993 Jul;101(suppl 1):4S-9S. http://www.ncbi.nlm.nih.gov/pubmed/8326154?tool=bestpractice.com (...) , Bartolucci AA, et al. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006 Apr;91(4):1345-50. http://jcem.endojournals.org/cgi/content/full/91/4/1345 http://www.ncbi.nlm.nih.gov/pubmed/16449347?tool=bestpractice.com Differentials Polycystic ovary syndrome Idiopathic hirsutism Hyperprolactinaemia Non-classic congenital adrenal hyperplasia Cushing's syndrome (benign) Androgenic medications Androgen

2018 BMJ Best Practice

179. Overview of brain tumours

, is the most common cause of Cushing's syndrome and is responsible for the majority of cases. Diagnosis is by demonstration of unsuppressed ACTH and subsequent cranial MRI. First-line therapy is generally transsphenoidal surgical resection. Benign prolactin-expressing and secreting pituitary adenoma. It is more frequent in women, mainly during the childbearing years. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485-534. http (...) . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697616/?tool=pubmed http://www.ncbi.nlm.nih.gov/pubmed/18226732?tool=bestpractice.com Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, et al. The role of primary pharmacological therapy in acromegaly. Pituitary. 2014;17(suppl 1):4-10. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906545/ http://www.ncbi.nlm.nih.gov/pubmed/24166706?tool=bestpractice.com Cushing's disease, which is hypercortisolism caused by an ACTH-secreting pituitary adenoma

2018 BMJ Best Practice

180. Overview of brain tumours

, is the most common cause of Cushing's syndrome and is responsible for the majority of cases. Diagnosis is by demonstration of unsuppressed ACTH and subsequent cranial MRI. First-line therapy is generally transsphenoidal surgical resection. Benign prolactin-expressing and secreting pituitary adenoma. It is more frequent in women, mainly during the childbearing years. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485-534. http (...) . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697616/?tool=pubmed http://www.ncbi.nlm.nih.gov/pubmed/18226732?tool=bestpractice.com Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, et al. The role of primary pharmacological therapy in acromegaly. Pituitary. 2014;17(suppl 1):4-10. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906545/ http://www.ncbi.nlm.nih.gov/pubmed/24166706?tool=bestpractice.com Cushing's disease, which is hypercortisolism caused by an ACTH-secreting pituitary adenoma

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>